About the eXalt3 Study

The eXalt3 clinical study is for adults with ALK+ lung cancer. On this study, we evaluate the safety of ensartinib compared to crizotinib (Xalkori), which is one of the current standard treatments of care, and see how tumors of patients previously untreated with an ALK inhibitor respond to this medication.

Contact us to join now

Who can participate?

You may be eligible to join the eXalt3 clinical study if you:

  • Are 18 years of age or older
  • Have been diagnosed with ALK+ lung cancer
  • Have not already received an ALK inhibitor for this disease

Locations

Globally, about 266 people with advanced lung cancer are planned to participate in the eXalt3 clinical research study. Click on the map below to see if there is a study site located near you. Additional study sites may open in the future.

Xcovery world map v3

About Ensartinib

Some genes can change and affect the way that tumors develop and grow. One example is the gene for anaplastic lymphoma kinase (ALK). Ensartinib, which is being tested in the eXalt3 study, acts specifically on tumors that have an altered ALK gene (ALK+ tumors). Xcovery’s previous research has theorized that ensartinib has the potential to block the effects of ALK. Moreover, preclinical research suggests that ensartinib can block ALK more strongly than other available cancer treatments.

What Happens During the Study?

If you are eligible and agree to participate in the eXalt3 clinical study, you will be required to:

  • Visit the study site as required by the study staff
  • Undergo study-related tests and procedures
  • Take ensartinib (or study medication) according to the instructions